Bethyl is now a part of Fortis Life Sciences. Learn more.

Overview of Cancer

Jump to Antibodies

Cancer Research is the study of the origins and molecular biology of tumor cells and mechanisms of oncogenesis. Cancer is characterized by dysregulated biochemical signaling, growth, and death processes of cells, often caused by specific genetic mutations. Determining the phenotype, lineage, and tissue origin of tumor cells helps to determine diagnosis and prognosis. Tumor cells exhibit metabolic abnormalities and develop mechanisms of angiogenesis, metastasis, and escape from the immune response to promote their own survival, growth, and spread. The goal is to understand the mechanisms of tumorigenesis in order to prevent the development of cancer and to develop effective treatments based on the unique properties of tumor cells.

Bethyl’s cancer portfolio contains over 4,000 antibodies. These antibodies have been manufactured on-site by our scientists. Our rigorous validation process ensures that the antibody will work in the applications outlined on the datasheet. These applications include: Western blot, immunohistochemistry, immunoprecipitation, immunocytochemistry, flow cytometry, proximity ligation assay, and ChIP. A Bethyl antibody is first validated for specificity in immunoprecipitation and/or western blot and if it passes our team will validate the antibody for additional applications. Our products are backed with a 100% guarantee to work in your assay, when used in under the same conditions outlined on the product datasheet, which provides confident, reliable results.

Bethyl sells a wide variety of antibodies for cancer research. Recent publications using our antibodies for studying cancer include:

  • Identifying two genes whose disruption have a direct effect on cancer severity1
  • Investigating how proteins associated with the DNA damage response can be targeted for cancer therapies2
  • Identifying the role of a non-coding RNA and how it may become a novel therapeutic target for the treatment of melanoma3
  • Understanding how mutations in BRCA1 can lead to genome instability and the disruption of DNA damage repair pathways4
  • Targeting the mRNA synthesis pathway as a potential therapeutic target for cancers driven by MYC5


Fluorescent detection of Lamin A/C, Matrin 3, and Beta-catenin in FFPE human prostate carcinoma by IHC.

Detection of human Lamin-A (green), Matrin 3 (red), and Beta-catenin (orange) in FFPE prostate carcinoma by IHC-IF. Antibodies: Rabbit anti-Lamin-A (A303-432A), rabbit anti-Matrin 3 (IHC-00081), and rabbit anti-Beta-catenin (IHC-00584). Secondary: DyLight® 488 conjugated goat anti-rabbit (A120-201D2), DyLight® 550 conjugated goat anti-rabbit (A120-201D3), DyLight® 594 conjugated goat anti-rabbit (A120-201D4).  Counterstain: DAPI (blue).

Detection of rpL7a /SURF3 in FFPE human colon carcinoma by IHC.

Detection of human rpL7a /SURF3 (red) in FFPE colon carcinoma by IHC-IF. Antibody: Rabbit anti-rpL7a/SURF3 (IHC-00454). Detection: DyLight® 594 conjugated goat anti-rabbit (A120-201D4).  Counterstain: DAPI (blue).

Detection of CD247/CD3Z in FFPE metastatic lymph node from lung cancer origin by IHC.

Detection of human CD247/CD3Z in FFPE metastatic lymph node from lung carcinoma by IHC. Antibody: Rabbit anti-CD247/CD3Z recombinant monoclonal [BL-336-1B2] (A700-017). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.


Below is the entire list of targets involved in cancer research. Can’t find what you are looking for? Bethyl offers a custom antibody service.




1.Gu YF. 2017. Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov. Aug;7(8):900-917. [Bethyl antibodies used: PB1/BAF180 Antibody (A301-591A) and HIF1-alpha Antibody (A300-286A)]

2. Capell, BC, Drake AM, Zhu J, Shah PP, Dou Z, Dorsey J, Simola DF, Donahue G, Sammons M, Rai TS, et al. 2016. MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev. Feb 1;30(3):321-336. [Bethyl antibody used: ATM Antibody (A300-299A)]

3. Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli C, Vanderheyden K, et al. 2016. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. Mar 24;531(7595):518-522. [Bethyl antibodies used: C1QBP (p32) Antibody (A302-863A) (This antibody was used in WB, IP, and ICC. Bethyl has not validated it for use in ICC nor IP and cannot guarantee the same results as published.) and XRN2 Antibody (A301-103A)]

4. Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Pathania S, McKinney KM, Eaton ML, et al. 2015. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol Cell. Feb 19;57(4):636-647. [Bethyl antibodies used: Senataxin Antibody (A301-105A) and BRC1 Antibody (A300-000A). These antibodies was used in ChIP. Bethyl has not validated them for use in ChIP and cannot guarantee the same results as published.]

5. Hsu, TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, et al. 2015. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. Sept 17:525(7569):384-388. [Bethyl antibody used: SF3a120/SAP114 Antibody (A301-603A)]